Skip to main content

Table 1 Patient and tumour characteristics

From: Proteomic biomarkers predicting lymph node involvement in serum of cervical cancer patients. Limitations of SELDI-TOF MS

 

Numerical display

LN positive (n = 12)

LN negative (n = 48)

Test

P value

Age in years

Mean (95%CI)

45.8 (38.5–53.0)

46.7 (43.3–50.0)

T-test

0.732

FIGO stage

 Ia2

n (%)

0 (0.0)

2 (4.2)

χ 2

0.134

 Ib1

n (%)

6 (50.0)

37 (77.1)

  

 Ib2

n (%)

2 (16.7)

2 (4.2)

  

 IIa

n (%)

4 (33.3)

7 (14.6)

  

Histological subtype

 Squamous cell carcinoma

n (%)

11 (91.7)

29 (60.4)

χ 2

0.119

 Adenocarcinoma

n (%)

1 (8.3)

17 (35.4)

  

 Adenosquamous carcinoma

n (%)

0 (0.0)

2 (4.2)

  

Lymph nodes

 Number of positive LN

Median (min-max)

1 (1–7)

0 (0–0)

Mann–Whitney

<0.001

 Number of removed LN

Median (min-max)

28 (4–50)

34 (18–89)

Mann–Whitney

0.241

LVSI

 Positive

n (%)

10 (83.3)

16 (33.3)

χ 2

0.005

 Negative

n (%)

2 (16.7)

32 (66.7)

  

Follow-up

 Follow-up (in months)

Mean (95%CI)

61.8 (42.0–81.5)

61.7 (49.0–66.5)

T-test

0.997

Recurrence

 Recurrence

n (%)

3 (25.0)

7 (14.6)

χ 2

0.665

 No recurrence

n (%)

9 (75.0)

41 (85.4)

  
  1. Abbreviations: LN = lymph node; FIGO = International Federation of Gynecology and Obstetrics; LVSI = lymphvascular space involvement.